Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|August 16, 2022

Early Intervention Strategies for Bipolar Disorder: Identifying Warning Signs

Author(s)Christopher Schneck, MD

What is a mood disorder and what are the early warning signs? What treatments are available?

Christopher Schneck, MD, gives a summary on his talk on bipolar disorder from the 2022 Annual Psychiatric Times™ World CME Conference.

Dr Schneck is the Division Head of Adult Psychiatry, the Chief of Service at CU Medicine Adult Outpatient Psychiatry, and Medical Director at the Helen and Arthur E. Johnson Depression Center Behavioral Health Director.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

The Art Wave/Adobe Stock

The 5 Faces of Bipolar Depression: A Case-Based Reflection

ByHameed Younis, MD

August 26th 2026

smoking cessation

Update on Varenicline for Smoking Cessation in Patients With Bipolar Disorder

ByDavid N. Osser, MD

August 18th 2026

bipolar

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

ByPragyan Sharma, MD, MSc,Samara White, PharmD,Ranel Troy Santos, PharmD, BCPP

August 5th 2026

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

ByLara Shirikjian, MD

July 31st 2026

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

ByGustavo Alva, MD, DFAPA

July 31st 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

DT120 (Lysergide) ODT Receives Breakthrough Therapy Designation for Treatment of MDD

New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose

Anita Clayton, MD, on Diagnosing and Discussing Sexual Dysfunction

The Postmodern Worldview and Contemporary Psychiatry

Morning Rounds: September 1-8